phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»10.37489/2587-7836-2026-2-90-100FPTZJQphkinetica-528Research ArticleТЕХНОЛОГИЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННЫХ СРЕДСТВТехнологические аспекты получения таблеток, диспергируемых в полости ртаTechnological aspects of the production of orodispersible tabletshttps://orcid.org/0000-0002-8321-6952ТишковС. В.TishkovS. V.

Тишков Сергей Валерьевич — к. фарм. н., в. н. с. лаборатории технологии лекарственных препаратов отдела качества и технологии лекарственных средств

Москва

Sergey V. Tishkov – PhD, Cand. Sci. (Pharm.), Leading Researcher of the Laboratory of Drug Technology of the Department of Quality and Technologyof Drugs

Moscow

tishkov_sv@academpharm.ruhttps://orcid.org/0009-0001-5572-9339ВуйновичД. Д.VuynovichD. D.

Вуйнович Данило Душкович — аспирант, ведущий инженер лаборатории технологии лекарственных препаратов отдела качества и технологии лекарственных средств

Москва

Danilo D. Vuynovich – Graduate Student, Leading Engineer of the Laboratory of Drug Technology of the Department of Quality and Technology of Drugs

Moscow

vuynovich_dd@academpharm.ruhttps://orcid.org/0000-0003-2930-9397МаркеевВ. Б.MarkeevV. B.

Маркеев Владимир Борисович — к. фарм. н., с. н. с. лаборатории технологии лекарственных препаратов отдела качества и технологии лекарственных средств

Москва

Vladimir B. Markeev – PhD, Cand. Sci. (Pharm.), Senior Researcher of the Laboratory of Drug Technology of the Department of Quality and Technologyof Drugs 

Moscow

markeev_vb@academpharm.ruhttps://orcid.org/0009-0001-7341-4584МистюковВ. Л.MistyukovV. L.

Мистюков Владислав Леонидович — аспирант, ведущий инженер лаборатории технологии лекарственных препаратов отдела качества и технологии лекарственных средств

Москва

Vladislav L. Mistyukov – Graduate Student, Leading Engineer of the Laboratory of Drug Technology of the Department of Quality and Technology of Drugs 

Moscow

mistyukov_vl@academpharm.ruhttps://orcid.org/0000-0002-7155-6714СергееваМ. С.SergeevaM. S.

Сергеева Мария Сергеевна — к. фарм. н., заведующий лабораторией стандартизации и контроля качества лекарственных средств отдела качества и технологии лекарственных средств

Москва

Mariya S. Sergeeva – PhD, Cand. Sci. (Pharm.), Head of the Laboratory of Drug Standardization and Quality control of the Department of Quality and Technology of Drugs

Moscow

sergeeva_ms@academpharm.ruhttps://orcid.org/0000-0002-9494-1332БлынскаяЕ. В.BlynskayaE. V.

Блынская Евгения Викторовна – д. фарм. н., заведующий лабораторией технологии лекарственных препаратов отдела качества и технологии лекарственных средств

Москва

Evgenia V. Blynskaya – PhD, Dr. Sci. (Pharm.), Head of the Laboratory of Drug Technology of the Department of Quality and Technology of Drugs

Moscow

blynskaya_ev@academpharm.ruhttps://orcid.org/0009-0004-3584-3742ДорофеевВ. Л.DorofeevV. L.

Дорофеев Владимир Львович – д. фарм. н., профессор, и. о. генерального директора

Москва

Vladimir L. Dorofeev – PhD, Dr. Sci. (Pharm), Professor, Acting General Director

Moscow

dorofeev_vl@academpharm.ruФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»РоссияFederal research center for innovator and emerging biomedical and pharmaceutical technologiesRussian Federation2026300620260290100Copyright © Тишков С.В., Вуйнович Д.Д., Маркеев В.Б., Мистюков В.Л., Сергеева М.С., Блынская Е.В., Дорофеев В.Л., 20262026Тишков С.В., Вуйнович Д.Д., Маркеев В.Б., Мистюков В.Л., Сергеева М.С., Блынская Е.В., Дорофеев В.Л.Tishkov S.V., Vuynovich D.D., Markeev V.B., Mistyukov V.L., Sergeeva M.S., Blynskaya E.V., Dorofeev V.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/528

Разработка состава и технологии получения таблеток, диспергируемых в полости рта, в настоящее время становится все более перспективной благодаря возможности их применения в педиатрической и гериатрической практике, в том числе пациентами с нарушением глотания или при отсутствии воды. В свою очередь, возможность обеспечивать всасываемость активной фармацевтической субстанции (АФС) через слизистую, минуя желудочно-кишечный тракт (ЖКТ), открывает новые возможности по предотвращению негативного воздействия на АФС кислой среды желудка и первичного пресистемного метаболизма. В статье представлен анализ основных методов и технологий производства таблеток, диспергируемых в полости рта, с примерами наиболее передовых технологий, а также применяемых вспомогательных веществ.

Development of the composition and manufacturing technology of orodispersible tablets (ODT) is becoming increasingly promising due to their applicability in pediatric and geriatric practice, including for patients with dysphagia or in the absence of water. Furthermore, the ability to ensure the absorption of the active pharmaceutical ingredient (API) through the oral mucosa, bypassing the gastrointestinal tract, opens up new opportunities for preventing the adverse effects of the acidic gastric environment and first-pass metabolism on the API. This article provides an overview of the principal methods and technologies for the production of ODT, featuring examples of the most advanced technologies, as well as the excipients employed.

таблеткидиспергируемые в полости ртаорально диспергируемые таблетки ОДТтехнологии производства ОДТпроцесс сублимацииtablets dispersible in the oral cavityorally disintegrating tablets ODTODT production technologiessublimation processРабота выполнена в рамках государственного задания Министерства науки и высшего образования Российской Федерации (FGFG -2025-0010)This work was conducted under the government contract of the Ministry of Science and Higher Education of the Russian Federation (FGFG -2025-0010)ReferencesАлексеев К.В., Блынская Е.В., Сизяков С.А. и др. Вспомогательные вещества в технологии таблеток с модифицированным высвобождением. Фармация. 2009;(6):49-56.[Alekseyev KV, Blynskaya YeV, Sizyakov SA, et al. Excipients in the technology of modified-release tablets. Farmatsiya. 2009;(6):49-56. (In Russ.)].Блынская Е.В., Тишков С.В., Алексеев К.В. Технологии трёхмерной печати для производства лекарственных форм. Разработка и регистрация лекарственных средств. 2018;(3):10-19.[Blynskaya EV, Tishkov SV, Alekseev KV. Three-dimensional printing technology for the production of dosage forms. Drug development & registration. 2018;(3):10-19. (In Russ.)].Тишков С.В., Гаврилов Д.И., Алексеев К.В. и др. Инновационные технологии производства таблеток-лиофилизатов и таблеток, диспергируемых в полости рта. Известия ГГТУ. Медицина, фармация. 2024;4(20);113-119.[Tishkov SV, Gavrilov DI, Alekseev KV, et al. Innovative technologies for the production of lyophilisate tablets and orally dispersible tablets. Izvestiya GGTU. Meditsina, farmatsiya. 2024;4(20):113-119. (In Russ.)]. doi: 10.51620/2687-1521-2024-4-20-113-119. EDN: HCTHCWШевченко А.М., Ковалевская Е.Г. Технологические особенности разработки состава и способов производства ородисперсных лекарственных форм. Разработка и регистрация лекарственных средств. 2014;1(6):26-30.[Shevchenko AM, Kovalevskaya EG. Technological features of the development and production methods orodispersible tablets. Razrabotka i registratsiya lekarstvennykh sredstv. 2014;1(6):26-30. (In Russ.)]. EDN: SHBHQZBrown D. Orally disintegrating tablets-taste over speed. Drug Del Technol. 2003;3:58-61.Brown D. Orally disintegrating tablets-taste over speed. Drug Del Technol. 2003;3:58-61.Deepak K. Orally disintegrating tablets. Tablets and Capsules. 2004;7:30-35.Deepak K. Orally disintegrating tablets. Tablets and Capsules. 2004;7:30-35.Chandrasekhar R, Hassan Z, Alhusban F, et al. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. Eur J Pharm Biopharm. 2009 May;72(1):119-29. doi: 10.1016/j.ejpb.2008.11.011.Chandrasekhar R, Hassan Z, Alhusban F, et al. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. Eur J Pharm Biopharm. 2009 May;72(1):119-29. doi: 10.1016/j.ejpb.2008.11.011.Fukami J, Yonemochi E, Yoshihashi Y, Terada K. Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose. Int J Pharm. 2006 Mar 9;310(1-2):101-9. doi: 10.1016/j.ijpharm.2005.11.041.Fukami J, Yonemochi E, Yoshihashi Y, Terada K. Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose. Int J Pharm. 2006 Mar 9;310(1-2):101-9. doi: 10.1016/j.ijpharm.2005.11.041.Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2(3):258-74. doi: 10.2174/187221108786241660.Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2(3):258-74. doi: 10.2174/187221108786241660.Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharmaceutical Technology. 2003;27(11):92-100.Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharmaceutical Technology. 2003;27(11):92-100.Koizumi K, Watanabe Y, Morita K, et al. New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm. 1997;152(1):127-131. doi: 10.1016/S0378-5173(97)04924-7.Koizumi K, Watanabe Y, Morita K, et al. New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm. 1997;152(1):127-131. doi: 10.1016/S0378-5173(97)04924-7.Ghosh TK, Pfister WR. Quick-Dissolving Oral Dosage Forms: Scientific and Regulatory Considerations from a Clinical Pharmacology and Biopharmaceutics Perspective. In: Ghosh TK, Pfister WR, eds. Drug Delivery to the Oral Cavity: Molecules to Market. New York, NY: Marcel Dekker; 2005:337-356.Ghosh TK, Pfister WR. Quick-Dissolving Oral Dosage Forms: Scientific and Regulatory Considerations from a Clinical Pharmacology and Biopharmaceutics Perspective. In: Ghosh TK, Pfister WR, eds. Drug Delivery to the Oral Cavity: Molecules to Market. New York, NY: Marcel Dekker; 2005:337-356.Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Release. 2005 Jun 20;105(1-2):16-22. doi: 10.1016/j.jconrel.2005.01.018.Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Release. 2005 Jun 20;105(1-2):16-22. doi: 10.1016/j.jconrel.2005.01.018.Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci. 2002 Apr;15(3):295-305. doi: 10.1016/s0928-0987(02)00011-8.Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci. 2002 Apr;15(3):295-305. doi: 10.1016/s0928-0987(02)00011-8.Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998 Apr;50(4):375-82. doi: 10.1111/j.2042-7158.1998.tb06876.x.Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998 Apr;50(4):375-82. doi: 10.1111/j.2042-7158.1998.tb06876.x.Corveleyn S, Remon JP. Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. Int J Pharm. 1998;166(1):65-74. doi: 10.1016/S0378-5173(98)00024-6.Corveleyn S, Remon JP. Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. Int J Pharm. 1998;166(1):65-74. doi: 10.1016/S0378-5173(98)00024-6.Dobetti L. Fast-melting tablets: Developments and technologies. Pharmaceutical Technology. 2001;(Suppl):44-50.Dobetti L. Fast-melting tablets: Developments and technologies. Pharmaceutical Technology. 2001;(Suppl):44-50.Bogner RH, Wilkosz MF. Fast-dissolving tablets: New dosage convenience for patients. US Pharmacist. 2002;27(3):34-43.Bogner RH, Wilkosz MF. Fast-dissolving tablets: New dosage convenience for patients. US Pharmacist. 2002;27(3):34-43.Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul. 2009 Jan;3(1):26-39. doi: 10.2174/187221109787158364.Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul. 2009 Jan;3(1):26-39. doi: 10.2174/187221109787158364.Sasidhar RLC, Vidyadhara S, Maheswari GV, et al. Solubility and dissolution rate enhancement of olmesartan medoxomil by complexation and development of mouth dissolving tablets. Advan. Biol. Res. 2013;7(2):32-41. doi: 10.5829/idosi.abr.2013.7.2.7244.Sasidhar RLC, Vidyadhara S, Maheswari GV, et al. Solubility and dissolution rate enhancement of olmesartan medoxomil by complexation and development of mouth dissolving tablets. Advan. Biol. Res. 2013;7(2):32-41. doi: 10.5829/idosi.abr.2013.7.2.7244.Parkash V, Maan S, Deepika, Yadav SK, Hemlata, Jogpal V. Fast disintegrating tablets: Opportunity in drug delivery system. J Adv Pharm Technol Res. 2011 Oct;2(4):223-35. doi: 10.4103/2231-4040.90877.Parkash V, Maan S, Deepika, Yadav SK, Hemlata, Jogpal V. Fast disintegrating tablets: Opportunity in drug delivery system. J Adv Pharm Technol Res. 2011 Oct;2(4):223-35. doi: 10.4103/2231-4040.90877.Gohel M, Patel M, Amin A, et al. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004 Apr 26;5(3):e36. doi: 10.1208/pt050336.Gohel M, Patel M, Amin A, et al. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004 Apr 26;5(3):e36. doi: 10.1208/pt050336.Lee KJ, Kang A, Delfino JJ, et al. Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form. Drug Dev Ind Pharm. 2003 Oct;29(9):967-79. doi: 10.1081/ddc-120025454.Lee KJ, Kang A, Delfino JJ, et al. Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form. Drug Dev Ind Pharm. 2003 Oct;29(9):967-79. doi: 10.1081/ddc-120025454.

The authors declare that there are no conflicts of interest present.